



## 2027 ASKP3 Annual Conference Call for Abstracts

### 1. Call For Abstract Primary Presenter

**Thank you for your interest in submitting an abstract for consideration as a presentation at the 2027 ASKP3 Annual Conference on January 28-30, in Austin, TX. Please note, we have a new addition and opportunity added for this year's submission process.**

**The ASKP3 Annual Conference is designed to provide a variety of educational topics that will advance the safe and ethical use of ketamine to treat mental health disorders and pain conditions.**

**In order to be considered, please complete your submission no later than 11:59 p.m. ET on Monday, June 15, 2026.**

**Submissions will be reviewed only if all required components are submitted before the submission close date.**

**Please ensure that all co-presenter information—including full contact details, professional designations, CVs, headshots, and bios—is submitted along with your abstract proposal to complete the submission process.**

**\*\*New Opportunity for 2027: ASKP3 is creating an Annual Conference Abstract Book with Digital Object Identifier (DOI) references. DOI publication is a permanent, citable link that allows the work to be reliably located and referenced overtime. This initiative will strengthen the academic and professional value of submissions; creating a visible body of work to inform education, advocacy and policy discussions in the field.**

**You may opt-in and provide additional details for your submission to be considered for the Digital Annual Conference Abstract Book. Or you may opt-out and use your abstract submission for presentation at the Annual Conference only.**

**Please contact ASKP3 Headquarters by emailing [info@askp.org](mailto:info@askp.org) with any questions.**

**Thank you for your submission and interest!**

\* 1. Primary Presenter Full Name (include designations)

\* 2. Primary Presenter Organization Name

\* 3. Primary Presenter Title

\* 4. Primary Presenter Email

\* 5. Primary Presenter Phone (best phone number for ASKP3 to reach you with any questions on your submission).

\* 6. Target Audience (Check all that apply.)

- Physicians
- Psychotherapists
- Therapists
- CRNAs
- Other Practitioners
- Other (please specify)

\* 7. Type of Presentation

- Main Stage Presentation (50 minutes)
- Concurrent Breakout Presentation (50 minutes)
- Poster Presentation

\* 8. Presentation Title (100 character limit)

\* 9. Brief description (100 word limit)

10. Link to publication (if data is published)

\* 11. Please list three (3) measurable learning objectives for your proposed session.

Your learning objectives should clearly describe what participants will be able to do after attending your session. Objectives must be written using action verbs that reflect observable and measurable outcomes.

Avoid vague terms like “understand” or “learn” and instead use specific, action verbs such as:

Identify  
Describe  
Demonstrate  
Apply  
Evaluate  
Compare  
Analyze

Example: "Evaluate the clinical protocols and safety considerations involved in the implementation of ketamine infusion therapy for treatment-resistant depression."

Objective 1

Objective 2

Objective 3

\* 12. Abstract Summary (500-word limit)

\* 13. Primary Presenter CV/Resume

Choose File

Choose File

No file chosen

\* 14. Primary Presenter Headshot

Choose File

Choose File

No file chosen

\* 15. Brief Primary Presenter Introduction Bio: Please provide a short introduction of the primary presenter (in third person) for credit approval and for use by the session moderator (LIMITED TO 150 CHARACTERS). Highlight your work and industry-related experience.

\* 16. Do you have co-presenters? (Please note Co-Presenter information **MUST** be completed before you submit your abstract)

Yes

No



## 2027 ASKP3 Annual Conference Call for Abstracts

### 2. Co-Presenter #1 Information

#### \* 17. Co-presenter #1 Information

First Name

Last Name

Designation(s)

Company/Organization

Title

Email

Phone Number

\* 18. Co-presenter #1 Brief Co-Presenter Introduction Bio: Please provide a short introduction of the co-presenter (in third person) for credit approval and for use by the session moderator (LIMITED TO 150 CHARACTERS). Highlight your work and industry-related experience.

#### \* 19. Add your co-presenter #1 CV/Resume

Choose File

Choose File

No file chosen

#### \* 20. Add your co-presenter #1 Headshot

Choose File

Choose File

No file chosen

\* 21. Will your session include any additional co-presenters or panelists? (Please note Co-Presenter information **MUST** be completed before you submit your abstract)

Yes

No



## 2027 ASKP3 Annual Conference Call for Abstracts

### 3. Co-Presenter #2 Information

#### \* 22. Co-presenter #2 Information

First Name

Last Name

Designation(s)

Company/Organization

Title

Email

Phone Number

\* 23. Co-presenter #2 Brief Co-Presenter #2 Introduction Bio: Please provide a short introduction of the co-presenter (in third person) for credit approval and for use by the session moderator (LIMITED TO 150 CHARACTERS). Highlight your work and industry-related experience.

#### \* 24. Add your co-presenter #2 CV/Resume

Choose File

Choose File

No file chosen

#### \* 25. Add your co-presenter #2 Headshot

Choose File

Choose File

No file chosen

\* 26. Will your session include any additional co-presenters or panelists? (Please note Co-Presenter information **MUST** be completed before you submit your abstract)

Yes

No



## 2027 ASKP3 Annual Conference Call for Abstracts

### 4. Co-Presenter #3 Information

#### \* 27. Co-presenter #3 Information

First Name	<input type="text"/>
Last Name	<input type="text"/>
Designation(s)	<input type="text"/>
Company/Organization	<input type="text"/>
Title	<input type="text"/>
Email	<input type="text"/>
Phone Number	<input type="text"/>

\* 28. Co-presenter #3 Brief Co-Presenter #3 Introduction Bio: Please provide a short introduction of the co-presenter (in third person) for credit approval and for use by the session moderator (LIMITED TO 150 CHARACTERS). Highlight your work and industry-related experience.

#### \* 29. Add your co-presenter #3 CV/Resume

No file chosen

#### \* 30. Add your co-presenter #3 Headshot

No file chosen

\* 31. Will your session include any additional co-presenters or panelists? (Please note Co-Presenter information MUST be completed before you submit your abstract)

Yes

No



## 2027 ASKP3 Annual Conference Call for Abstracts

### 5. Co-Presenter #4 Information

#### \* 32. Co-presenter #4 Information

First Name

Last Name

Designation(s)

Company/Organization

Title

Email

Phone Number

\* 33. Co-presenter #4 Brief Co-Presenter #4 Introduction Bio: Please provide a short introduction of the co-presenter (in third person) for credit approval and for use by the session moderator (LIMITED TO 150 CHARACTERS). Highlight your work and industry-related experience.

#### \* 34. Add your co-presenter #4 CV/Resume

Choose File

Choose File

No file chosen

#### \* 35. Add your co-presenter #4 Headshot

Choose File

Choose File

No file chosen



2027 ASKP3 Annual Conference Call for Abstracts

6. Session Information

\* 36. Have you presented this session previously? If yes, when, where, and for whom?

- No  
 Yes

If yes, please specify:

\* 37. Have you presented for ASKP3 before?

- Yes  
 No

38. Please list any outstanding questions or concerns that might affect your engagement at this Conference.

\* 39. We ask all submitters to be transparent about any relationships — financial or otherwise — that could be seen as influencing your research or conclusions. This helps our reviewers and audience assess the work fairly.

Examples include funding from pharmaceutical or device companies, consulting arrangements, speaking fees, or ownership stakes in relevant organizations.

Do any authors or presenters have a conflict of interest to report?

- Yes (please describe below)
- No (input N/A below)

\* 40. Conflict of Interest Disclosure (Max 300 characters). Please enter N/A if not applicable.

41. What % of this submission used AI tools to construct? Please enter N/A if not applicable.

\* 42. IRB / Ethics Status (Select one.). Please enter N/A if not applicable.

- Approved
- Exempt
- Not required
- Pending
- Not Applicable

43. Funding Source (Optional | Max 150 characters)

\* 44. Prior Presentation / Publication (Required) (Select one.)

- No
- Yes, presented
- Yes, published
- Yes, presented and published

45. If yes, please specify details (Conditional | Max 300 characters)

**\* 46. DOI (Digital Object Identifier) Publication Consent (Required)**

If accepted, abstracts are eligible for DOI assignment and publication in the ASKP3 proceedings.

- Yes, include my abstract in DOI-indexed proceedings
- No, do not include in proceedings

**\* 47. Submission Integrity Statement (All four conditions required)**

- This submission is original.
- Information provided is accurate.
- This is not promotional content.
- I understand submission requirements.

**\* 48. Are you interested in having your abstract considered for publication in the 2027 ASKP3 Annual Conference Abstract Book with DOI references?**

- Yes, I am interested (must complete additional questions).
- No, I am not interested (submitting for Conference presentation consideration only).



## 2027 ASKP3 Annual Conference Call for Abstracts

### 7. Abstract Publication Opportunity

**New for 2027, ASKP3 is creating an Annual Conference Abstract Book with DOI (Digital Object Identifier) references.**

**DOI publication means a unique digital identifier is assigned to the content, creating a permanent, citable link that allows the work to be reliably located and referenced over time. This initiative is intended to strengthen the academic and professional value of submissions, support citable outputs for presenters, and contribute to a more visible and organized body of work that can inform education, advocacy, and policy discussions.**

**Submissions intended for DOI publication will follow a more structured abstract format, including defined sections, category selection, and additional detail to support peer review and publication standards.**

**If you are interested in having your abstract considered for publication in the Book, please complete the fields below.**



## 2027 ASKP3 Annual Conference Call for Abstracts

### 8. Abstract Content

**Instructions: Please complete all sections below. Total abstract length should not exceed ~300 words. Character limits are applied to support consistency in peer review and publication. Submissions that substantially exceed limits may be returned or rejected without review.**

\* 49. Abstract Title (Max 150 characters)

\* 50. Abstract Category (Select One)

- Original Research:** Hypothesis-driven or exploratory studies using systematic methods to generate new, generalizable knowledge, with defined methodology and results.
- Clinical Case Study:** Descriptions of single or multiple patients or cases that highlight clinical observations, interventions, or outcomes, with relevance to practice.
- Quality Improvement:** Systematic, data-driven efforts to improve clinical care, safety, or operational processes within a real-world setting, with measurable outcomes.
- Conceptual / Policy:** Analyses, frameworks, or recommendations addressing clinical, ethical, regulatory, or policy issues, without primary data collection.
- Educational Innovation:** Development, implementation, or evaluation of novel educational programs, curricula, or training approaches, with defined learner outcomes.
- Proposed Research (with expected conclusions):** Planned or in-progress studies outlining a clear hypothesis, methodology, and anticipated outcomes or implications.

**\* 51. Primary Topic Areas (Select all that apply.)**

- Clinical Practice (Mental Health)
- Pain Management
- Psychedelic Medicine / Ketamine Therapy
- Safety / Standards / Protocols
- Nursing / Clinical Operations
- Psychotherapy / Integration
- Education / Training
- Policy / Advocacy
- Research Methods / Data Science
- Other (please specify)

**\* 52. Keywords (3-5)**

Keywords are collected alongside DOI (Digital Object Identifier) data primarily to maximize the discoverability, categorization, and tracking of research works within academic databases and search engines. They act as essential metadata that connect, index, and organize digital content for future retrieval by other researchers.

**\* 53. Background / Introduction (Max 500 characters)**

Provide the context, rationale, or problem being addressed.

**\* 54. Objective / Hypothesis (Max 300 characters)**

State the purpose of the work, research question, hypothesis, or central aim.

**\* 55. Methods / Approach (Max 800 characters)**

Describe the study design, cases, intervention, framework, educational model, or analytic approach used.

**\* 56. Results / Findings / Expected Conclusions (Max 800 characters)**

Provide key findings, observed outcomes, or expected conclusions if the work is proposed and not yet complete.

\* 57. Conclusion / Implications (Max 400 characters)

Describe the relevance, significance, or implications for practice, policy, education, or future research.



2027 ASKP3 Annual Conference Call for Abstracts

9. Category-Specific Questions- If Original Research


\* 58. Study Design (Select all that apply.)

- Randomized controlled trial
- Observational study
- Retrospective review
- Prospective cohort
- Qualitative study
- Mixed methods
- Survey-based study
- Other (please specify)

\* 59. Sample Size (Check only one.)

- Under 10 patients
- 11-50 patients
- 51-100 patients
- 101-200 patients
- 201-500 patients
- 501-1000 patients
- Over 1000 patients

60. Data Analysis Approach (Optional | Max 600 characters)





2027 ASKP3 Annual Conference Call for Abstracts

10. Category-Specific Questions- If Clinical Case Study

\* 61. Number of Cases

\* 62. Clinical Focus / Condition / Intervention (Max 400 characters)

\* 63. Outcomes Observed (Max 600 characters)



2027 ASKP3 Annual Conference Call for Abstracts

11. Category-Specific Questions- If Quality Improvement

\* 64. Clinical, operational, or educational Setting (Max 400 characters)

\* 65. Intervention / Process Change (Max 400 characters)

\* 66. Outcome Measures (Max 400 characters)



2027 ASKP3 Annual Conference Call for Abstracts

12. Category-Specific Questions- If Conceptual / Policy

\* 67. Problem Statement (Max 400 characters)

\* 68. Proposed Framework / Recommendation (Max 600 characters)



2027 ASKP3 Annual Conference Call for Abstracts

13. Category-Specific Questions- If Educational Innovation

\* 69. Target Learners

\* 70. Educational Intervention (Max 600 characters)

\* 71. Evaluation / Outcomes (Max 400 characters)



2027 ASKP3 Annual Conference Call for Abstracts

14. Category-Specific Questions- If Proposed Research

72. Proposed Study Design

- Randomized controlled trial
- Observational study
- Retrospective review
- Prospective cohort
- Qualitative study
- Mixed methods
- Survey-based study
- Other (please specify)

\* 73. Expected Conclusions (Max 600 characters)

\* 74. Project Status

- Concept
- IRB pending
- Data collection underway
- Analysis underway
- Near completion



2027 ASKP3 Annual Conference Call for Abstracts

15. Final Confirmation

\* 75. Final Confirmation

I have reviewed my submission and understand edits may not be possible after submission